124072-81-7

Basic information

• Product Name: (R)-N-BOC-N,N-DIMETHYL-L-PROLINAMIDE
• Synonyms: (R)-N-BOC-N,N-DIMETHYL-L-PROLINAMIDE
• CAS NO: 124072-81-7
• Molecular Formula: C12H22 N2 O3
• Molecular Weight: 0
• Mol File: 124072-81-7.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-N-BOC-N,N-DIMETHYL-L-PROLINAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-N-BOC-N,N-DIMETHYL-L-PROLINAMIDE(124072-81-7)
• EPA Substance Registry System: (R)-N-BOC-N,N-DIMETHYL-L-PROLINAMIDE(124072-81-7)

Safety Data

• Hazardous Substances Data: 124072-81-7(Hazardous Substances Data)

Usage

General Description

The chemical (R)-N-BOC-N,N-DIMETHYL-L-PROLINAMIDE is a compound that is commonly used as a reagent in organic synthesis. It is a derivative of proline and belongs to the class of amides. (R)-N-BOC-N,N-DIMETHYL-L-PROLINAMIDE is often utilized as a chiral reagent in asymmetric synthesis, particularly in the formation of chiral ketones and aldehydes. It is also used in the preparation of pharmaceutical compounds and other organic products. With its unique chemical properties, (R)-N-BOC-N,N-DIMETHYL-L-PROLINAMIDE plays a crucial role in the production of chiral molecules and is widely used in the field of organic chemistry.

Upstream product

• 37784-17-1 N-(tert-butoxycarbonyl)-D-proline 
• 124-40-3 dimethyl amine 

Downstream Products

• 566159-08-8 (2R)-N,N-dimethylpyrrolidine-2-carboxamide 

Relevant articles and documents

New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists

Vasopressin (AVP) is a hormone that stimulates an increase in water permeability through activation of V2 receptors in the kidney. The analogue of AVP, desmopressin, has proven an effective drug for diseases where a reduction of urine output is desired. However, its peptidic nature limits its bioavailability. We report herein the discovery of potent, nonpeptidic, benzylurea derived agonists of the vasopressin V2 receptor. We describe substitutions on the benzyl group to give improvements in potency and subsequent modifications to the urea end group to provide improvements in solubility and increased oral efficacy in a rat model of diuresis. The lead compound 20e (VA106483) is reported for the first time and has been selected for clinical development.